VivoSim Labs Inc. (VIVS)
NASDAQ: VIVSHealthcareBiotechnologyUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
VIVS stock chart
Technical analysisKey statistics
All statistics- Market cap
- $2.94M
- EPS (TTM)
- -$4.47
- Dividend yield
- None
- 52-week range
- 0.17 – 3.41
- Day range
- 0.1746 – 0.1944
- Volume / Avg
- 860.74K / 5.85M
- Beta
- —
- Shares outstanding
- 16.59M
- Next earnings
- Nov 5, 2026
52-week range
VIVS stock today
On Oct 8, VIVS ended the session at $0.1772, shedding $0.0143 (7.47%), versus the S&P 500's 0.47% decline. Trading was light, with 860.74K shares changing hands, about 15% of the average daily volume. At this level, VIVS sits near the bottom of its 52-week range of $0.17 to $3.41: 94.8% below the high and 4.2% above the low.
VivoSim Labs has posted a net loss over the last twelve months (EPS of -$4.47), so its P/E ratio is not meaningful. VivoSim Labs's next earnings report is expected on Nov 5, 2026.
Summary generated from market data by MetaCap's automated system. Methodology
About VivoSim Labs
Company profileVivoSim Labs, Inc., a pharmaceutical and biotechnology services company, provides testing of drugs and drug candidates in three-dimensional (3D) human tissue models of liver and intestine. It offers partners liver and intestinal toxicology insights through its new approach methodologies (NAM) models. The company also provides liver toxicology predictive screening and research services, as well as works on predicting and studying the intestinal side effect profiles of drugs that are therapeutic candidates of pharmaceutical and biotech companies at various stages of drug development; and build functional 3D human tissues through its proprietary technologies that mimic key aspects of native human tissue composition, architecture, function, and disease.
- Sector
- Healthcare
- Industry
- Biotechnology
- Headquarters
- San Diego, CA
- Employees
- 15
- Website
- vivosim.ai
Earnings
Earnings history- Next report
- Nov 5, 2026
VivoSim Labs peers
Healthcare sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SILOSilo Pharma Inc. | 1.45 | +0.69% | $2.98M | vs VIVS |
| GOVXGeoVax Labs Inc. | 0.2866 | -0.97% | $2.90M | vs VIVS |
| MLECMoolec Science SA | 4.19 | -12.89% | $3.04M | vs VIVS |
| REVBRevelation Biosciences Inc. | 0.7739 | -6.55% | $3.08M | vs VIVS |
| MTNBMatinas Biopharma Holdings Inc. | 2.83 | +2.17% | $2.77M | vs VIVS |
| MBIOMustang Bio Inc. | 0.417 | -7.37% | $3.16M | vs VIVS |
| VRAXVirax Biolabs Group Limited | 1.99 | -5.69% | $2.68M | vs VIVS |
| KAPAKairos Pharma Ltd. | 0.9595 | +10.29% | $3.25M | vs VIVS |
Indexes, lists and sector
Appears in lists
VivoSim Labs stock FAQ
What is VivoSim Labs's stock price today?
VIVS last traded at $0.1772 as of Oct 8, 4:00 PM EDT, down 7.47% on the day. Prices are delayed at least 15 minutes.
When is VivoSim Labs's next earnings date?
VivoSim Labs is expected to report earnings on Thursday, November 5, 2026.
What is the VIVS 52-week high?
The 52-week high for VIVS is $3.41 and the 52-week low is $0.17. The stock is currently 94.8% below its high.